Key Insights from Attending ASH 2025
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Key Insights from Attending ASH 2025
-
Narrado por:
-
De:
Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC
Recorded on December 18, 2025
Lore Gruenbaum, PhD
Chief Scientific Officer & Senior Vice President of Research
Blood Cancer United
Washington, DC
Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know!
Additional Blood Cancer United Resources:
- Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education
- Blood Cancer United Resources for Patients
Todavía no hay opiniones